Katsuya Nakamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katsuya Nakamura has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
Yoshiki Sekijima
19 shared publicationsShu-Ichi Ikeda
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
12 shared publicationsTsuneaki Yoshinaga
Center for Medical Genetics, Shinshu University Hospital, Japan
8 shared publicationsKunihiro Yoshida
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
7 shared publicationsTomoki Kosho
Center for Medical Genetics, Shinshu University Hospital, Japan
7 shared publications- Kunihiro Yoshida
Shinshu University School of Medicine
6 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Journal of Human Genetics
Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan
Recent advances in hereditary dementia research have clarified its molecular pathogenesis and clinical applications, with several advances already reaching implementation. The late 2023 introduction of anti-amyloid β therapies for Alzheimer’s disease (AD) in Japan marked the beginning of a transformative era, though amyloid-related imaging abnormalities (ARIA) remain a notable adverse effect. Because APOE genotype, and ε4 dose in particular, is a major determinant of ARIA, genotyping is now embedded in pretreatment assessment. This review examines how one national health system has incorporated these advances and distinguishes between two frequently conflated domains: real-world clinical practice and clinical research. Practically, we describe the Guidelines for the Appropriate Use of APOE Genetic Testing in Dementia, established in 2025 and revised in 2026 following national health insurance approval, which position APOE testing as a pharmacogenetic tool governing monitoring intensity rather than treatment eligibility. We consider what the lower ε4 allele frequency in Japan implies, now that per-genotype effect estimates have been revised to values comparable to those in European-ancestry populations, and we set out the counseling required when a pharmacogenetic result carries risk information for untested relatives. On the research side, we describe the Hereditary Dementia Trial Ready Cohort, a national registry spanning 21 causative genes, and explain why its scope diverges from that of autosomal dominant AD-focused international initiatives such as DIAN. We conclude that features of the Japanese experience are most likely to be transferred to other healthcare systems.
- 4 November 2026
- Published by Springer Nature in Journal of Human Genetics
Open AccessClinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan
Recent advances in hereditary dementia research have clarified its molecular pathogenesis and clinical applications, with several advances already reaching implementation. The late 2023 introduction of anti-amyloid β therapies for Alzheimer’s disease (AD) in Japan marked the beginning of a transformative era, though amyloid-related imaging abnormalities (ARIA) remain a notable adverse effect. Because APOE genotype, and ε4 dose in particular, is a major determinant of ARIA, genotyping is now embedded in pretreatment assessment. This review examines how one national health system has incorporated these advances and distinguishes between two frequently conflated domains: real-world clinical practice and clinical research. Practically, we describe the Guidelines for the Appropriate Use of APOE Genetic Testing in Dementia, established in 2025 and revised in 2026 following national health insurance approval, which position APOE testing as a pharmacogenetic tool governing monitoring intensity rather than treatment eligibility. We consider what the lower ε4 allele frequency in Japan implies, now that per-genotype effect estimates have been revised to values comparable to those in European-ancestry populations, and we set out the counseling required when a pharmacogenetic result carries risk information for untested relatives. On the research side, we describe the Hereditary Dementia Trial Ready Cohort, a national registry spanning 21 causative genes, and explain why its scope diverges from that of autosomal dominant AD-focused international initiatives such as DIAN. We conclude that features of the Japanese experience are most likely to be transferred to other healthcare systems.
- 1 May 2026
- Published by Springer Nature in neurogenetics
- Vol. 27 (1)
Internal carotid and vertebrobasilar artery dolichoectasia in patients with cerebral small vessel disease and COL4A1/COL4A2 duplication
Hereditary cerebral small vessel disease (CSVD) associated with duplication involving region 13q34, which includes both COL4A1/COL4A2 is relatively rare. Here, we report a Japanese family with this duplication along with dilation and tortuosity in the multiple intracranial arteries. A 44-year-old man and his father experienced a lacunar infarction. Brain magnetic resonance imaging revealed multiple white matter hyperintensities and abnormal elongation and tortuosity of the ICA/VA. Genetic studies revealed a distal duplication at 13q34. Our cases suggest that dilation and tortuosity of the multiple intracranial artery may be a distinguishing neuroradiological feature of patients with CSVD caused by COL4A1/COL4A2 duplication. Ryotaro Yui, Teruya Morizumi and Nobuhiko Ohashi contributed equally to this work and share first authorship.
- 1 May 2026
- Published by Springer Nature in neurogenetics
- Vol. 27 (1)
Internal carotid and vertebrobasilar artery dolichoectasia in patients with cerebral small vessel disease and COL4A1/COL4A2 duplication
Hereditary cerebral small vessel disease (CSVD) associated with duplication involving region 13q34, which includes both COL4A1/COL4A2 is relatively rare. Here, we report a Japanese family with this duplication along with dilation and tortuosity in the multiple intracranial arteries. A 44-year-old man and his father experienced a lacunar infarction. Brain magnetic resonance imaging revealed multiple white matter hyperintensities and abnormal elongation and tortuosity of the ICA/VA. Genetic studies revealed a distal duplication at 13q34. Our cases suggest that dilation and tortuosity of the multiple intracranial artery may be a distinguishing neuroradiological feature of patients with CSVD caused by COL4A1/COL4A2 duplication. Ryotaro Yui, Teruya Morizumi and Nobuhiko Ohashi contributed equally to this work and share first authorship.
- Open Access
- 11 February 2026
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
A novel PSEN2 missense variant in a Japanese woman with hereditary Alzheimer's disease
Hereditary Alzheimer's disease (hAD) and PSEN2 variants are rare, and the benefit of anti-amyloid β-directed monoclonal antibody (mAb) therapy is unknown. We encountered a 51-year-old Japanese woman with PSEN2 -associated hAD. A molecular diagnosis revealed a novel uniallelic missense variant (NM_000447:c.356T > G, p.Leu119Arg) in PSEN2 . Intravenous mAb therapy was initiated at age 50, and serial amyloid positron emission tomography showed intense Pittsburgh compound B accumulation and a reduction in amyloid-β deposits in the cerebral cortex after 6 months. Our results suggest that treatment with mAbs has the potential to reduce amyloid deposits in the brain, even in patients with symptomatic hAD.
- 11 February 2026
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
Open AccessA novel PSEN2 missense variant in a Japanese woman with hereditary Alzheimer's disease
Hereditary Alzheimer's disease (hAD) and PSEN2 variants are rare, and the benefit of anti-amyloid β-directed monoclonal antibody (mAb) therapy is unknown. We encountered a 51-year-old Japanese woman with PSEN2 -associated hAD. A molecular diagnosis revealed a novel uniallelic missense variant (NM_000447:c.356T > G, p.Leu119Arg) in PSEN2 . Intravenous mAb therapy was initiated at age 50, and serial amyloid positron emission tomography showed intense Pittsburgh compound B accumulation and a reduction in amyloid-β deposits in the cerebral cortex after 6 months. Our results suggest that treatment with mAbs has the potential to reduce amyloid deposits in the brain, even in patients with symptomatic hAD.
- Open Access
- 1 January 2026
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 66 (1) , 19-22
A 57-year-old male case of high temperature requirement A serine peptidase 1 (HTRA1)-related cerebral small vessel disease with “Chocolate Chip Sign” on susceptibility-weighted imaging
症例は57歳男性である.父親に50代後半から複数回の脳梗塞の既往があった.57歳から脳梗塞を繰り返し精査目的に入院した.頭部MRI FLAIRで深部白質にびまん性の高信号域を認め,脳小血管病が疑われた.また,中脳表面にドット様のSWI低信号域の多発(“Chocolate Chip Sign”)がありhigh temperature requirement A serine peptidase 1(HTRA1)関連脳小血管病を疑い,遺伝学的検査を提出した.HTRA1遺伝子にミスセンスバリアント(NM 00275.4:c.754G>A, p.Ala252Thr)をヘテロ接合性に認め,確定診断した.“Chocolate Chip Sign” がHTRA1関連脳小血管病の診断に有用である.
- 1 January 2026
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 66 (1) , 19-22
Open AccessA 57-year-old male case of high temperature requirement A serine peptidase 1 (HTRA1)-related cerebral small vessel disease with “Chocolate Chip Sign” on susceptibility-weighted imaging
症例は57歳男性である.父親に50代後半から複数回の脳梗塞の既往があった.57歳から脳梗塞を繰り返し精査目的に入院した.頭部MRI FLAIRで深部白質にびまん性の高信号域を認め,脳小血管病が疑われた.また,中脳表面にドット様のSWI低信号域の多発(“Chocolate Chip Sign”)がありhigh temperature requirement A serine peptidase 1(HTRA1)関連脳小血管病を疑い,遺伝学的検査を提出した.HTRA1遺伝子にミスセンスバリアント(NM 00275.4:c.754G>A, p.Ala252Thr)をヘテロ接合性に認め,確定診断した.“Chocolate Chip Sign” がHTRA1関連脳小血管病の診断に有用である.
- Open Access
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e101422
A novel missense variant of PSEN2 in a Japanese woman with hereditary Alzheimer's disease
Background: Heterozygous variants of APP , PSEN1 , and PSEN2 have been reported as causative for hereditary Alzheimer's disease (AD); however, patients with PSEN2 variants are relatively rare. Method: We performed clinical and genetic laboratory evaluation of a patient with hereditary AD. Result: The patient, a 51‐year‐old Japanese woman, was born to non‐consanguineous parents. She had a family history of young onset dementia in her mother. At age 45, her husband first noticed her amnesia, and her cognitive function gradually declined. At age 48, she was referred to our hospital. Results of neuropsychological and neuroradiological studies, including brain MRI and amyloid PET, were consistent with those of AD. By multi‐gene sequencing related to AD, we identified novel heterozygous missense variants in PSEN2 (c.356T>G, p.Leu119Arg). At age 50, intravenous treatment with lecanemab was initiated. Conclusion: In this study, we report the first hereditary AD patient with a PSEN2 variant from Japan, and will discuss the clinical and genetic characteristics of patients with novel PSNE2 variants.
- 23 December 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (S6) , e101422
Open AccessA novel missense variant of PSEN2 in a Japanese woman with hereditary Alzheimer's disease
Background: Heterozygous variants of APP , PSEN1 , and PSEN2 have been reported as causative for hereditary Alzheimer's disease (AD); however, patients with PSEN2 variants are relatively rare. Method: We performed clinical and genetic laboratory evaluation of a patient with hereditary AD. Result: The patient, a 51‐year‐old Japanese woman, was born to non‐consanguineous parents. She had a family history of young onset dementia in her mother. At age 45, her husband first noticed her amnesia, and her cognitive function gradually declined. At age 48, she was referred to our hospital. Results of neuropsychological and neuroradiological studies, including brain MRI and amyloid PET, were consistent with those of AD. By multi‐gene sequencing related to AD, we identified novel heterozygous missense variants in PSEN2 (c.356T>G, p.Leu119Arg). At age 50, intravenous treatment with lecanemab was initiated. Conclusion: In this study, we report the first hereditary AD patient with a PSEN2 variant from Japan, and will discuss the clinical and genetic characteristics of patients with novel PSNE2 variants.
- Open Access
- 25 November 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (11) , e70044
A Novel Synonymous Variant in SQSTM1 Causes Neurodegeneration With Ataxia, Dystonia, and Gaze Palsy Revealed by Urine‐Derived Cells‐Based Functional Analysis
Background: Heterozygous variants of sequestosome‐1 gene (SQSTM1) have been reported in patients with various neurological disorders, whereas biallelic pathogenic variants of SQSTM1 can cause child‐onset and multisystem neurodegeneration, including cerebellar ataxia, dystonia, and vertical gaze palsy (NADGP). Here, we describe two cases of NADGP in a Japanese family.Methods: We performed clinical and genetic laboratory evaluations of the two patients and their healthy parents.Results: By whole‐exome sequencing, we identified compound heterozygous variants in SQSTM1(NM_003900.5): c.1A>G p.(Met1?) in the initial codon, and c.969G>A, located at the 3′ end of exon 6, which is novel and seemingly a synonymous but is actually a truncating variant causing aberrant splicing. An SQSTM1 protein expression assay using urine‐derived cells (UDCs) demonstrated that both variants (c.1A>G and c.969G>A) were unable to induce normal splicing of premessenger RNA. Cerebellar ataxia is a characteristic manifestation of this disorder; however, brain magnetic resonance imaging studies have not shown significant cerebellar atrophy. Our patients experienced chorea during adolescence.Conclusions: Only a few reports have highlighted the presence of chorea; however, our findings suggest that NADGP should be considered as a differential diagnosis of hereditary chorea. This study also demonstrates the utility of UDCs, obtained using noninvasive approaches, in functionally analyzing genetic diseases.
- 25 November 2024
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 12 (11) , e70044
Open AccessA Novel Synonymous Variant in SQSTM1 Causes Neurodegeneration With Ataxia, Dystonia, and Gaze Palsy Revealed by Urine‐Derived Cells‐Based Functional Analysis
Background: Heterozygous variants of sequestosome‐1 gene (SQSTM1) have been reported in patients with various neurological disorders, whereas biallelic pathogenic variants of SQSTM1 can cause child‐onset and multisystem neurodegeneration, including cerebellar ataxia, dystonia, and vertical gaze palsy (NADGP). Here, we describe two cases of NADGP in a Japanese family.Methods: We performed clinical and genetic laboratory evaluations of the two patients and their healthy parents.Results: By whole‐exome sequencing, we identified compound heterozygous variants in SQSTM1(NM_003900.5): c.1A>G p.(Met1?) in the initial codon, and c.969G>A, located at the 3′ end of exon 6, which is novel and seemingly a synonymous but is actually a truncating variant causing aberrant splicing. An SQSTM1 protein expression assay using urine‐derived cells (UDCs) demonstrated that both variants (c.1A>G and c.969G>A) were unable to induce normal splicing of premessenger RNA. Cerebellar ataxia is a characteristic manifestation of this disorder; however, brain magnetic resonance imaging studies have not shown significant cerebellar atrophy. Our patients experienced chorea during adolescence.Conclusions: Only a few reports have highlighted the presence of chorea; however, our findings suggest that NADGP should be considered as a differential diagnosis of hereditary chorea. This study also demonstrates the utility of UDCs, obtained using noninvasive approaches, in functionally analyzing genetic diseases.
- 7 October 2024
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 67 (3) , 281-282
Clinical genetic approaches to the management of patients with myotonic dystrophy type 1 and their families
This commentary is on the original article by Trucco et al. on pages 365–373 of this issue.
- 7 October 2024
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 67 (3) , 281-282
Clinical genetic approaches to the management of patients with myotonic dystrophy type 1 and their families
This commentary is on the original article by Trucco et al. on pages 365–373 of this issue.
- Open Access
- 1 April 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (7) , 1005-1008
Auditory Neuropathy Spectrum Disorder Progressing with Motor and Sensory Neuropathy Caused by an ATP1A1 Variant
We encountered a 27-year-old Japanese woman with sensorineural deafness progressing to motor and sensory neuropathy. At 16 years old, she had developed weakness in her lower extremities and hearing impairment, which gradually deteriorated. At 22 years old, combined audiological, electrophysiological, and radiological examination results were consistent with auditory neuropathy spectrum disorder (ANSD). Genetic analyses identified a previously reported missense variant in the ATP1A1 gene (NM_000701.8:c.1799C>G, p.Pro600Arg). Although sensorineural deafness has been reported as a clinical manifestation of ATP1A1-related disorders, our case suggested that ANSD may underlie the pathogenesis of deafness in ATP1A1-related disorders. This case report broadens the genotype-phenotype spectrum of ATP1A1-related disorders.
- 1 April 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (7) , 1005-1008
Open AccessAuditory Neuropathy Spectrum Disorder Progressing with Motor and Sensory Neuropathy Caused by an ATP1A1 Variant
We encountered a 27-year-old Japanese woman with sensorineural deafness progressing to motor and sensory neuropathy. At 16 years old, she had developed weakness in her lower extremities and hearing impairment, which gradually deteriorated. At 22 years old, combined audiological, electrophysiological, and radiological examination results were consistent with auditory neuropathy spectrum disorder (ANSD). Genetic analyses identified a previously reported missense variant in the ATP1A1 gene (NM_000701.8:c.1799C>G, p.Pro600Arg). Although sensorineural deafness has been reported as a clinical manifestation of ATP1A1-related disorders, our case suggested that ANSD may underlie the pathogenesis of deafness in ATP1A1-related disorders. This case report broadens the genotype-phenotype spectrum of ATP1A1-related disorders.
- Open Access
- 15 October 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (20) , 3047-3051
Long-term Observation of a Japanese Patient with a Multiple-system Neurodegenerative Disorder with a Uniallelic de novo Missense Variant in KIF1A
We encountered a 37-year-old Japanese man with KIF1A-associated neurological disorder (KAND) who exhibited motor developmental delay, intellectual disability, and slowly progressive cerebellar ataxia, hypotonia, and optic neuropathy. Pyramidal tract signs were evident late in this case. At 30 years old, the patient developed a neurogenic bladder. A molecular diagnosis revealed a uniallelic missense de novo variant (p.L278P) of KIF1A. Serial neuroradiological studies revealed atrophy of the cerebellum at an early age, and cerebral hemisphere atrophy progressed slowly over a 22-year observation period. Our study suggests that the primary etiology of KAND may be acquired, long-standing neurodegeneration rather than congenital hypoplasia.
- 15 October 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (20) , 3047-3051
Open AccessLong-term Observation of a Japanese Patient with a Multiple-system Neurodegenerative Disorder with a Uniallelic de novo Missense Variant in KIF1A
We encountered a 37-year-old Japanese man with KIF1A-associated neurological disorder (KAND) who exhibited motor developmental delay, intellectual disability, and slowly progressive cerebellar ataxia, hypotonia, and optic neuropathy. Pyramidal tract signs were evident late in this case. At 30 years old, the patient developed a neurogenic bladder. A molecular diagnosis revealed a uniallelic missense de novo variant (p.L278P) of KIF1A. Serial neuroradiological studies revealed atrophy of the cerebellum at an early age, and cerebral hemisphere atrophy progressed slowly over a 22-year observation period. Our study suggests that the primary etiology of KAND may be acquired, long-standing neurodegeneration rather than congenital hypoplasia.
- Open Access
- 7 September 2023
- Published by Wiley in JIMD Reports
- Vol. 64 (6) , 410-416
Lysinuric protein intolerance exhibiting renal tubular acidosis/Fanconi syndrome in a Japanese woman
Lysinuric protein intolerance (LPI), caused by pathogenic variants of SLC7A7, is characterized by protein aversion, failure to thrive, hyperammonemia, and hepatomegaly. Recent studies have reported that LPI can cause multiple organ dysfunctions, including kidney disease, autoimmune deficiency, pulmonary alveolar proteinosis, and osteoporosis. We report the case of a 47-year-old Japanese woman who was initially diagnosed with renal tubular acidosis (RTA), Fanconi syndrome, and rickets. At the age of 3 years, she demonstrated a failure to thrive. Urinary amino acid analysis revealed elevated lysine and arginine levels, which were masked by pan-amino aciduria. She was subsequently diagnosed with rickets at 5 years of age and RTA/Fanconi syndrome at 15 years of age. She was continuously treated with supplementation of vitamin D3, phosphate, and bicarbonate. A renal biopsy at 18 years of age demonstrated diffuse proximal and distal tubular damage with endocytosis-lysosome pathway abnormalities. Distinctive symptoms of LPI, such as protein aversion and postprandial hyperammonemia were not observed throughout the patient's clinical course. The patient underwent a panel-based comprehensive genetic testing and was diagnosed with LPI. As the complications of LPI involve many organs, patients lacking distinctive symptoms may develop various diseases, including RTA/Fanconi syndrome. Our case indicates that proximal and distal tubular damages are notable findings in patients with LPI. The possibility of LPI should be carefully considered in the management of RTA/Fanconi syndrome and/or incomprehensible pathological tubular damage, even in the absence of distinctive symptoms; furthermore, a comprehensive genetic analysis is useful for diagnosing LPI.
- 7 September 2023
- Published by Wiley in JIMD Reports
- Vol. 64 (6) , 410-416
Open AccessLysinuric protein intolerance exhibiting renal tubular acidosis/Fanconi syndrome in a Japanese woman
Lysinuric protein intolerance (LPI), caused by pathogenic variants of SLC7A7, is characterized by protein aversion, failure to thrive, hyperammonemia, and hepatomegaly. Recent studies have reported that LPI can cause multiple organ dysfunctions, including kidney disease, autoimmune deficiency, pulmonary alveolar proteinosis, and osteoporosis. We report the case of a 47-year-old Japanese woman who was initially diagnosed with renal tubular acidosis (RTA), Fanconi syndrome, and rickets. At the age of 3 years, she demonstrated a failure to thrive. Urinary amino acid analysis revealed elevated lysine and arginine levels, which were masked by pan-amino aciduria. She was subsequently diagnosed with rickets at 5 years of age and RTA/Fanconi syndrome at 15 years of age. She was continuously treated with supplementation of vitamin D3, phosphate, and bicarbonate. A renal biopsy at 18 years of age demonstrated diffuse proximal and distal tubular damage with endocytosis-lysosome pathway abnormalities. Distinctive symptoms of LPI, such as protein aversion and postprandial hyperammonemia were not observed throughout the patient's clinical course. The patient underwent a panel-based comprehensive genetic testing and was diagnosed with LPI. As the complications of LPI involve many organs, patients lacking distinctive symptoms may develop various diseases, including RTA/Fanconi syndrome. Our case indicates that proximal and distal tubular damages are notable findings in patients with LPI. The possibility of LPI should be carefully considered in the management of RTA/Fanconi syndrome and/or incomprehensible pathological tubular damage, even in the absence of distinctive symptoms; furthermore, a comprehensive genetic analysis is useful for diagnosing LPI.